Table 2.
Canonical pathways affected by furan at 2 mg/kg bw/day in males and females
| Female | Male | ||||
|---|---|---|---|---|---|
| Ingenuity canonical pathways | −log (p value) | Ratio | Ingenuity canonical pathways | −log (p value) | Ratio |
| Glutathione-mediated detoxification | 2.99 | 0.07 | LPS/IL-1-mediated inhibition of RXR function | 11 | 0.114 |
| LPS/IL-1-mediated inhibition of RXR function | 2.97 | 0.03 | Acute phase response signaling | 8.25 | 0.116 |
| NRF2-mediated oxidative stress response | 2.73 | 0.03 | Nicotine degradation II | 6.23 | 0.129 |
| Hepatic fibrosis/hepatic stellate cell activation | 2.49 | 0.03 | LXR/RXR activation | 6.05 | 0.108 |
| Aryl hydrocarbon receptor signaling | 2.48 | 0.03 | Coagulation system | 5.49 | 0.211 |
| Histamine degradation | 2.42 | 0.07 | Bupropion degradation | 5.39 | 0.212 |
| Fatty acid α oxidation | 2.24 | 0.09 | Acetone degradation I (to methylglyoxal) | 5.27 | 0.194 |
| Oxidative ethanol degradation III | 2.24 | 0.05 | Nicotine degradation III | 5.05 | 0.123 |
| Putrescine degradation III | 2.19 | 0.07 | PXR/RXR activation | 4.95 | 0.109 |
| 2-Amino-3-carboxymuconate semialdehyde degradation to glutaryl-CoA | 2.15 | 0.09 | Melatonin degradation I | 4.84 | 0.136 |
| Methylglyoxal degradation VI | 2.15 | 0.08 | Xenobiotic metabolism signaling | 4.82 | 0.073 |
| Tryptophan degradation X (Mammalian, via Tryptamine) | 2.14 | 0.07 | FXR/RXR activation | 4.72 | 0.1 |
| Ethanol degradation IV | 2.14 | 0.07 | Complement system | 4.64 | 0.2 |
| Acute phase response signaling | 2.13 | 0.03 | Superpathway of melatonin Degradation | 4.52 | 0.111 |
| cardiomyocyte differentiation via BMP receptors | 2.10 | 0.09 | Methylglyoxal degradation III | 4.48 | 0.227 |
| Granulocyte adhesion and diapedesis | 2.08 | 0.03 | Estrogen biosynthesis | 4.22 | 0.143 |
| RAR activation | 2.05 | 0.03 | Tryptophan degradation X (mammalian, via tryptamine) | 4.05 | 0.172 |
| Ethanol degradation II | 3.66 | 0.14 | |||
| Bile acid biosynthesis, neutral pathway | 3.52 | 0.069 | |||
| Noradrenaline and adrenaline degradation | 3.44 | 0.113 | |||
| Dopamine degradation | 3.42 | 0.132 | |||
| Extrinsic prothrombin activation pathway | 3.14 | 0.182 | |||
| Oxidative ethanol degradation III | 3.14 | 0.1 | |||
| Intrinsic prothrombin activation pathway | 3.09 | 0.135 | |||
| Ethanol degradation IV | 2.93 | 0.138 | |||
| Serotonin degradation | 2.92 | 0.09 | |||
| Aryl hydrocarbon receptor signaling | 2.84 | 0.064 | |||
| Retinol biosynthesis | 2.64 | 0.111 | |||
| Granulocyte adhesion and diapedesis | 2.57 | 0.066 | |||
| NRF2-mediated oxidative stress response | 2.45 | 0.062 | |||
| Inhibition of matrix metalloproteases | 2.43 | 0.125 | |||
| Thyroid cancer signaling | 2.38 | 0.114 | |||
| Serine biosynthesis | 2.38 | 0.154 | |||
| d-Glucuronate degradation I | 2.38 | 0.143 | |||
| EIF2 signaling | 2.37 | 0.06 | |||
| Histamine degradation | 2.34 | 0.103 | |||
| Atherosclerosis signaling | 2.24 | 0.065 | |||
| Fatty Acid α oxidation | 2.08 | 0.13 | |||
| Putrescine degradation III | 2 | 0.1 | |||
| Proline biosynthesis II (from arginine) | 2 | 0.1 | |||
| Superpathway of serine and glycine biosynthesis I | 2 | 0.111 | |||
| Arginine degradation VI (arginase 2 pathway) | 2 | 0.125 | |||
| Superoxide radicals degradation | 2 | 0.25 | |||
| Tyrosine degradation I | 2 | 0.133 | |||
| Bladder cancer signaling | 2 | 0.072 | |||
−log (p value) cutoff at 2, bold font indicates common pathways between males and females, ratio indicates the number of significant genes to the total number of genes in the pathway